Mercedes-Benz Joins The Climate Pledge and Delivers More Than 1,800 Electric Vehicles to Amazon’s Delivery Fleet in Europe
28.8.2020 10:01:00 EEST | Business Wire | Press release
Today, Amazon (NASDAQ: AMZN) announced it is adding more than 1,800 electric vehicles from Mercedes-Benz Vans to its delivery fleet in Europe this year. Amazon and Mercedes-Benz share a commitment to reduce emissions from the transportation sector, and Mercedes-Benz also announced today it has joined The Climate Pledge, which calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Agreement goal of 2050.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005049/en/
Electric vehicle (Photo: Business Wire)
“We welcome the bold leadership demonstrated by Mercedes-Benz by signing up to The Climate Pledge and committing to ambitious action to address climate change. We need continued innovation and partnership from auto manufacturers like Mercedes-Benz to decarbonize the transportation sector and tackle the climate crisis,” said Jeff Bezos, Amazon founder and CEO. “Amazon is adding 1,800 electric delivery vehicles from Mercedes-Benz as part of our journey to build the most sustainable transportation fleet in the world, and we will be moving fast to get these vans on the road this year.”
“At Mercedes-Benz, we have set ourselves the ambitious target to make the transformation of mobility a success story. By joining ‘The Climate Pledge’ we are building on our goal to consistently pursue emission-free mobility and sustainable vehicle production,” said Ola Källenius, Chairman of the Board of Management of Daimler AG and Mercedes-Benz AG. “We stand with Amazon, Global Optimism and the other signatories of The Climate Pledge, in a commitment to being net zero carbon by 2040 – ten years ahead of The Paris Agreement. I am pleased that we will be able to gain even more momentum on our sustainability offensive with this step.”
As part of Mercedes-Benz’s commitment as the latest signatory of The Climate Pledge, the company is doubling down on its commitment to "Ambition2039," a roadmap to CO2-neutral mobility. The company is evaluating ways to remove carbon from its entire value chain, from development to the supplier network, from its own production to the electrification of products and beyond, as well as to ensuring renewable energies for the use phase of electric vehicles. With its goal to have a CO2-neutral fleet of new cars in less than 20 years, Mercedes-Benz is making an important contribution to slowing climate change. The company is already making good progress in this direction: By the end of this year, the vehicle portfolio will comprise five fully electric models and more than 20 plug-in hybrids. Signatories to The Climate Pledge also have the opportunity to share access to technologies, best practices and innovations in supply chain enhancements. They are also able to co-invest in new technologies and emerging solutions.
Amazon’s Delivery Service Partners will have access to the new fleet of zero-emission vehicles to make deliveries to customers in Europe this year, helping to save thousands of metric tons of carbon. The order is a milestone for Mercedes-Benz Vans, marking the largest order of electric vehicles for the manufacturer to date, and makes Amazon its largest sustainable transportation partner worldwide. More than 1,200 EVs in the order will be comprised of the newest electric commercial van available at Mercedes-Benz – the eSprinter, a larger model than the manufacturer’s first zero-emission vehicle, the eVito. The eSprinter includes state-of-the-art safety features including, electrical parking brake, active brake assist, reverse camera, blind spot assist, and more. The remaining 600 vehicles will be comprised of the manufacturer’s midsize electric van, the eVito, to give Delivery Service Partners operating in geographies that require a smaller-format vehicle access to a zero-emissions delivery option.
"I am delighted that we are further intensifying our long-standing partnership with Amazon and working together on the battery-electric future of transportation," said Marcus Breitschwerdt, Head of Mercedes-Benz Vans. “With the eVito and the eSprinter, we have electric vehicles in our portfolio, which are ideally suited for the requirements of the courier-, express- and parcel-service industry for goods delivery on the so-called ‘last mile’ in terms of their equipment and range. They show that local emission-free driving, convincing performance, comfort and low operating costs can be combined perfectly.”
“Amazon’s investment is a strong and concrete sign of its commitment and alignment to EU priorities,” said Fabio Massimo Castaldo, Vice President at the European Parliament. “Amazon continues to contribute to the achievement of the EU Green Deal goals, foster technological innovation and generate resilient and sustainable jobs in Europe. I hope that other corporations will follow Amazon’s example in the near future.”
Amazon is also committed to powering its growing electric fleet with clean energy. As part of The Climate Pledge, Amazon is investing in renewable energy as a critical step toward addressing our carbon footprint globally and has committed to run on 100% renewable energy by 2025. Globally, Amazon has 91 renewable energy projects that have the capacity to generate over 2,900 MW and deliver more than 7.5 million MWh of energy annually. These projects include 31 utility-scale wind and solar renewable energy projects and 60 solar rooftops on fulfillment centers and sort centers around the globe.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit www.amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005049/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom